About CMC Biologics
CMC Biologics is a Healthcare company based in Copenhagen (Denmark) founded in 2001, and was acquired by AGC in December 2016. CDMO offering microbial and mammalian cell culture (including perfusion production) based services. The company has 1,264 employees. Its focus areas include Biopharma Outsourcing, CDMO and Biologics. Its legal entity is AGC BIOLOGICS A/S.
Company details
CMC Biologics provides biopharmaceutical contract manufacturing services. It offers microbial fermentation and mammalian cell culture based cGMP manufacturing services, such as process development and scale-up of protein processes; and production of biopharmaceuticals for pre-clinical, clinical trials, and market supply. CMC Biologics claims to be one of the few CDMOs that are capable of offering mammalian perfusion production services which include BioSEP, ATF and other perfusion technologies. CMC Biologics also has a proprietary CHEF1 Expression Platform for quicker and effective development through mammalian cell lines. The company also provides consultancy in facility design, quality, and regulatory issues; technology evaluation, analytical development and quality control services. The company has FDA MHRA approved manufacturing facilities (with both single-use and stainless steel bioreactors) in Copenhagen, Seattle and Berkeley and claims to have completed 120 projects right from preclinical supply to commercial production. The company was acquired by Japans AGC Asahi Glass in December 2016.
- Headquarters Copenhagen, Denmark
- Employees 1,264
- Stage Acquired
- SectorsHealthcare
- Website cmcbio.com
- Social LinkedIn
- Acquired by AGC (Dec 2016)
- Legal Name Agc Biologics A/S
Funding Insights of CMC Biologics
- Total Rounds 2
- Investors Count 3
All 2 funding rounds of CMC Biologics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2008 | Private Equity Round | – | – | ||
| Jun 2004 | Private Equity Round | – | – |
4 investors in total: 4 institutional.
Investors in CMC Biologics
CMC Biologics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include AGC, Monitor Clipper Partners and European Equity Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Monitor Clipper Partners is engaged in middle-market private equity investments. | monitorclipper.com | Cambridge, United States | ||
Investment in life sciences companies is facilitated by EEP. | eeplp.com | London, United Kingdom | ||
| innoven-partners.com | ||||
AGC is engaged in manufacturing glass and chemical products. | 2000 | agc.com | Tokyo, Japan |
Investor details for CMC Biologics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of CMC Biologics
4 dated milestones of CMC Biologics across 15 years, from founding to its latest funding, stage changes and deals.
- Founded CMC Biologics is founded.
- Funding First funding round.
- Funding Latest funding round, Private Equity Round,.
- Exit Acquired by AGC.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cmc Biologics
Complete news archive for CMC Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CMC Biologics
CMC Biologics was founded in 2001 and raised its 1st funding round 3 years after it was founded.
CMC Biologics is headquartered in Copenhagen, Denmark.
CMC Biologics has 1,264 employees.
Annual revenue of CMC Biologics is $55.44M as on Dec 31, 2014.
CMC Biologics provides biopharmaceutical contract manufacturing services. It offers microbial fermentation and mammalian cell culture based cGMP manufacturing services, such as process development and scale-up of protein processes; and production of biopharmaceuticals for pre-clinical, clinical trials, and market supply. CMC Biologics claims to be one of the few CDMOs that are capable of offering mammalian perfusion production services which include BioSEP, ATF and other perfusion technologies. CMC Biologics also has a proprietary CHEF1 Expression Platform for quicker and effective development through mammalian cell lines. The company also provides consultancy in facility design, quality, and regulatory issues; technology evaluation, analytical development and quality control services. The company has FDA MHRA approved manufacturing facilities (with both single-use and stainless steel bioreactors) in Copenhagen, Seattle and Berkeley and claims to have completed 120 projects right from preclinical supply to commercial production. The company was acquired by Japans AGC Asahi Glass in December 2016.
CMC Biologics has 4 investors. Key investors include AGC, Monitor Clipper Partners, European Equity Partners, and Innoven Partners.
CMC Biologics operates through Agc Biologics A/S.
Yes. CMC Biologics was acquired by AGC in December 2016.